Cargando…
ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas
Gliomas are the most aggressive primary intracranial malignancies with poor overall survival. ITGA5 is one member of the integrin adhesion molecule family and is implicated in cancer metastasis and oncogenesis. However, few studies have explored the association between tumor immune microenvironment...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971292/ https://www.ncbi.nlm.nih.gov/pubmed/35371978 http://dx.doi.org/10.3389/fonc.2022.844144 |
_version_ | 1784679602911707136 |
---|---|
author | Li, Shuyu Zhang, Nan Liu, Shiyang Zhang, Hao Liu, Jiajing Qi, Yiwei Zhang, Qi Li, Xingrui |
author_facet | Li, Shuyu Zhang, Nan Liu, Shiyang Zhang, Hao Liu, Jiajing Qi, Yiwei Zhang, Qi Li, Xingrui |
author_sort | Li, Shuyu |
collection | PubMed |
description | Gliomas are the most aggressive primary intracranial malignancies with poor overall survival. ITGA5 is one member of the integrin adhesion molecule family and is implicated in cancer metastasis and oncogenesis. However, few studies have explored the association between tumor immune microenvironment and ITGA5 expression level in gliomas. Firstly, we analyzed 3,047 glioma patient samples collected from the TCGA, the CGGA, and the GEO databases, proving that high ITGA5 expression positively related to aggressive clinicopathological features and poor survival in glioma patients. Then, based on the ITGA5 level, immunological characteristics and genomic alteration were explored through multiple algorithms. We observed that ITGA5 was involved in pivotal oncological pathways, immune-related processes, and distinct typical genomic alterations in gliomas. Notably, ITGA5 was found to engage in remolding glioma immune infiltration and immune microenvironment, manifested by higher immune cell infiltration when ITGA5 is highly expressed. We also demonstrated a strong correlation between ITGA5 and immune checkpoint molecules that may be beneficial from immune checkpoint blockade strategies. In addition, ITGA5 was found to be a robust and sensitive indicator for plenty of chemotherapy drugs through drug sensitivity prediction. Altogether, our comprehensive analyses deciphered the prognostic, immunological, and therapeutic value of ITGA5 in glioma, thus improving individual and precise therapy for combating gliomas. |
format | Online Article Text |
id | pubmed-8971292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89712922022-04-02 ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas Li, Shuyu Zhang, Nan Liu, Shiyang Zhang, Hao Liu, Jiajing Qi, Yiwei Zhang, Qi Li, Xingrui Front Oncol Oncology Gliomas are the most aggressive primary intracranial malignancies with poor overall survival. ITGA5 is one member of the integrin adhesion molecule family and is implicated in cancer metastasis and oncogenesis. However, few studies have explored the association between tumor immune microenvironment and ITGA5 expression level in gliomas. Firstly, we analyzed 3,047 glioma patient samples collected from the TCGA, the CGGA, and the GEO databases, proving that high ITGA5 expression positively related to aggressive clinicopathological features and poor survival in glioma patients. Then, based on the ITGA5 level, immunological characteristics and genomic alteration were explored through multiple algorithms. We observed that ITGA5 was involved in pivotal oncological pathways, immune-related processes, and distinct typical genomic alterations in gliomas. Notably, ITGA5 was found to engage in remolding glioma immune infiltration and immune microenvironment, manifested by higher immune cell infiltration when ITGA5 is highly expressed. We also demonstrated a strong correlation between ITGA5 and immune checkpoint molecules that may be beneficial from immune checkpoint blockade strategies. In addition, ITGA5 was found to be a robust and sensitive indicator for plenty of chemotherapy drugs through drug sensitivity prediction. Altogether, our comprehensive analyses deciphered the prognostic, immunological, and therapeutic value of ITGA5 in glioma, thus improving individual and precise therapy for combating gliomas. Frontiers Media S.A. 2022-03-18 /pmc/articles/PMC8971292/ /pubmed/35371978 http://dx.doi.org/10.3389/fonc.2022.844144 Text en Copyright © 2022 Li, Zhang, Liu, Zhang, Liu, Qi, Zhang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Shuyu Zhang, Nan Liu, Shiyang Zhang, Hao Liu, Jiajing Qi, Yiwei Zhang, Qi Li, Xingrui ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas |
title | ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas |
title_full | ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas |
title_fullStr | ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas |
title_full_unstemmed | ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas |
title_short | ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas |
title_sort | itga5 is a novel oncogenic biomarker and correlates with tumor immune microenvironment in gliomas |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971292/ https://www.ncbi.nlm.nih.gov/pubmed/35371978 http://dx.doi.org/10.3389/fonc.2022.844144 |
work_keys_str_mv | AT lishuyu itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas AT zhangnan itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas AT liushiyang itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas AT zhanghao itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas AT liujiajing itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas AT qiyiwei itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas AT zhangqi itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas AT lixingrui itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas |